(S)-3-((S)-2-Acetylamino-3-methyl-butyrylamino)-N-{(S)-1-[(2S,3R)-2-((S)-2-hydroxy-5-oxo-tetrahydro-furan-3-ylcarbamoyl)-3-phenyl-pyrrolidine-1-carbonyl]-2-methyl-propyl}-succinamic acid

ID: ALA1835318

PubChem CID: 56677088

Max Phase: Preclinical

Molecular Formula: C31H43N5O10

Molecular Weight: 645.71

Molecule Type: Small molecule

This compound is available for customization.

Associated Items:

Bioactivity Summary Target Summary Assay Summary

Names and Identifiers

Canonical SMILES: CC(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N1CC[C@H](c2ccccc2)[C@H]1C(=O)N[C@H]1CC(=O)OC1O)C(C)C)C(C)C

Standard InChI: InChI=1S/C31H43N5O10/c1-15(2)24(32-17(5)37)28(42)33-20(13-22(38)39)27(41)35-25(16(3)4)30(44)36-12-11-19(18-9-7-6-8-10-18)26(36)29(43)34-21-14-23(40)46-31(21)45/h6-10,15-16,19-21,24-26,31,45H,11-14H2,1-5H3,(H,32,37)(H,33,42)(H,34,43)(H,35,41)(H,38,39)/t19-,20+,21+,24+,25+,26+,31?/m1/s1

Standard InChI Key: XUOCLTMBEMBDPW-RTBQYLKVSA-N

Molfile:

     RDKit          2D

 46 48  0  0  0  0  0  0  0  0999 V2000
   17.6069  -16.3686    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.8849  -18.5833    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.2112  -19.0595    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.4554  -19.8485    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   17.2815  -19.8624    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.5458  -19.0797    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.7593  -20.5350    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   15.4338  -18.7961    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   16.9010  -17.7587    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   16.1486  -17.4149    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.4876  -16.1022    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   16.1530  -16.5899    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.8237  -16.1093    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.5716  -15.3210    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.7475  -15.3204    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3456  -16.1022    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.0573  -15.6897    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.6298  -15.6897    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3456  -16.9272    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.7732  -16.1022    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.4891  -15.6897    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.7732  -16.9272    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.0573  -17.3397    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.4891  -17.3397    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.2008  -16.1022    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.4891  -14.8647    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   11.9166  -15.6897    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.6325  -16.1022    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.9166  -14.8647    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.6325  -16.9272    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   12.6325  -14.4522    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.3492  -14.8658    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   12.6333  -13.6283    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   13.3442  -15.6897    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.0601  -16.1022    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.7718  -15.6897    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.0601  -16.9272    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.3442  -17.3397    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.7718  -17.3397    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.7718  -14.8647    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   15.4533  -17.8589    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   17.7683  -17.1768    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.5507  -17.4362    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.1678  -16.8874    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.9973  -16.0758    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.2152  -15.8202    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
 12 10  1  1
  2  6  1  0
  5  7  2  0
  3  8  1  0
  2  9  1  1
 10  9  1  0
 11 12  1  0
  2  3  1  0
  3  4  1  0
 16 17  1  0
 16 18  1  0
 16 19  2  0
 17 20  1  0
 20 21  1  0
 20 22  1  6
 22 23  1  0
 22 24  1  0
 21 25  1  0
 21 26  2  0
 25 27  1  0
 27 28  1  0
 27 29  1  1
 28 30  2  0
 29 31  1  0
 31 32  1  0
 31 33  2  0
 28 34  1  0
 34 35  1  0
 35 36  1  0
 35 37  1  6
 37 38  1  0
 37 39  1  0
 36 11  1  0
 36 40  2  0
  4  5  1  0
 10 41  2  0
 13  1  1  6
  5  6  1  0
  1 42  2  0
 12 13  1  0
 42 43  1  0
 13 14  1  0
 43 44  2  0
 14 15  1  0
 44 45  1  0
 15 11  1  0
 45 46  2  0
 46  1  1  0
M  END

Associated Targets(Human)

CASP2 Tchem Caspase-2 (173 Activities)

Discover Target: CASP2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CASP3 Tchem Caspase-3 (3632 Activities)

Discover Target: CASP3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Natural Product: No	Oral: No	Chemical Probe: No	Parenteral: No
Molecule Type: Small molecule	Topical: No	First In Class: No	Black Box: No
Chirality: No	Availability: No	Prodrug: No

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 645.71	Molecular Weight (Monoisotopic): 645.3010	AlogP: -0.62	#Rotatable Bonds: 13
Polar Surface Area: 220.54	Molecular Species: ACID	HBA: 9	HBD: 6
#RO5 Violations: 2	HBA (Lipinski): 15	HBD (Lipinski): 6	#RO5 Violations (Lipinski): 3
CX Acidic pKa: 4.26	CX Basic pKa: ┄	CX LogP: -0.66	CX LogD: -3.66
Aromatic Rings: 1	Heavy Atoms: 46	QED Weighted: 0.15	Np Likeness Score: 0.29

References

1. Maillard MC, Brookfield FA, Courtney SM, Eustache FM, Gemkow MJ, Handel RK, Johnson LC, Johnson PD, Kerry MA, Krieger F, Meniconi M, Muñoz-Sanjuán I, Palfrey JJ, Park H, Schaertl S, Taylor MG, Weddell D, Dominguez C.. (2011) Exploiting differences in caspase-2 and -3 S₂ subsites for selectivity: structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors., 19 (19): [PMID:21903398] [10.1016/j.bmc.2011.08.020]
2. Chen, Yi-Hua YH and 9 more authors. 2006-03-09 Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. [PMID:16509578]
3. Maillard, Michel C MC and 17 more authors. 2011-10-01 Exploiting differences in caspase-2 and -3 S₂ subsites for selectivity: structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors. [PMID:21903398]

(S)-3-((S)-2-Acetylamino-3-methyl-butyrylamino)-N-{(S)-1-[(2S,3R)-2-((S)-2-hydroxy-5-oxo-tetrahydro-furan-3-ylcarbamoyl)-3-phenyl-pyrrolidine-1-carbonyl]-2-methyl-propyl}-succinamic acid

Names and Identifiers

Alternative Forms

Associated Targets(Human)

Molecule Features

Drug Indications

Mechanisms of Action

Biocomponents

Calculated Properties

References

Source